Two federal health officials with long track records managing key aspects of the 340B program are playing pivotal roles in a major overhaul of the U.S. Centers for Disease Control and Prevention.
CDC Director Rochelle Walensky last month named Mary
…
U.S. Health and Human Services Secretary Xavier Becerra told members of Congress on Thursday that his department is doing all it can with the tools it has to address drug manufacturers’ denials of 340B pricing involving contract pharmacies.
If lawmakers
…
The potential cost to the U.S. government next year of remedying unlawful Medicare Part B drug payment cuts for 340B hospitals could be higher than federal Medicare officials think.
The U.S. Centers for Medicare & Medicaid Services in mid-July put
…
The U.S. Center for Medicare & Medicaid Services encouraged health care providers on its blog last month “to prepare for the end” of its COVID-19 waivers and flexibilities “as soon as possible and to begin moving forward to reestablishing previous
…
Top U.S. House Republicans sent U.S. Health and Human Services Secretary Xavier Becerra a letter on Monday asking 18 detailed questions about implementation and oversight of the Inflation Reduction Act’s (IRA) Medicare drug price negotiation provisions. Their interrogation foreshadows intensified
…
Generic drug manufacturer Unichem Pharmaceuticals USA must repay 340B covered entities for overcharges found during a 340B program compliance audit, the U.S. Health Resources and Services Administration (HRSA) said yesterday.
HRSA has been auditing five drug manufacturers per year for
…
Congress and the White House should let financially distressed critical access hospitals keep their 340B drug discounts if they opt under a new law to downgrade into emergency hospitals to remain solvent, rural health advocates told federal health officials in
…
In its mid-year report released this month, Fitch Ratings predicts a “deteriorating” outlook for nonprofit hospitals and health systems through the remainder of 2022 and into 2023. This is primarily driven by the “macro headwinds” of high labor costs and
…
The landmark prescription drug pricing legislation that President Joe Biden signed this month is a mixed bag for 340B stakeholders, 340B Health Publisher and CEO Ted Slafsky says in his latest column for Omnicell.
Biden signed the Inflation Reduction Act on
…*Sign up for news summaries and alerts from 340B Report
